Propanc Biopharma, Inc. financial data

Symbol
PPCB on OTC
Location
302/6 Butler Street, Camberwell, Victoria, Australia
Fiscal year end
June 30
Latest financial report
Sep 29, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 99.7 % +3531%
Debt-to-equity 78.3 %
Return On Equity -993 % -2014%
Return On Assets -557 % +59.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.8M shares -98.1%
Common Stock, Shares, Outstanding 11.6M shares
Entity Public Float 47.9K USD -88.7%
Common Stock, Value, Issued 11.6K USD
Weighted Average Number of Shares Outstanding, Basic 3.97M shares
Weighted Average Number of Shares Outstanding, Diluted 3.97M shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 224K USD -9.83%
General and Administrative Expense 57M USD +4448%
Operating Income (Loss) -57.3M USD -3629%
Nonoperating Income (Expense) -1.65M USD -298%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -58.9M USD -2922%
Income Tax Expense (Benefit) -275 USD +84%
Net Income (Loss) Attributable to Parent -58.9M USD -3137%
Earnings Per Share, Basic -14 USD/shares -946%
Earnings Per Share, Diluted -14 USD/shares +99%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.2K USD -30.4%
Other Assets, Current 1.38K USD -1.85%
Assets, Current 8.35M USD +32732%
Property, Plant and Equipment, Net 50 USD -95.4%
Operating Lease, Right-of-Use Asset 59.4K USD +234%
Assets 19.6M USD +27029%
Accounts Payable, Current 1.25M USD +2.99%
Employee-related Liabilities, Current 668K USD +4.46%
Liabilities, Current 5.58M USD +47.1%
Operating Lease, Liability, Noncurrent 24.9K USD
Liabilities 5.73M USD +48.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.32M USD +3.89%
Retained Earnings (Accumulated Deficit) -126M USD -88.3%
Stockholders' Equity Attributable to Parent 13.9M USD
Liabilities and Equity 19.6M USD +27029%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -236K USD +29.4%
Net Cash Provided by (Used in) Financing Activities 216K USD -38.4%
Common Stock, Shares Authorized 10B shares 0%
Common Stock, Shares, Issued 11.6M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.8K USD -245%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.61K USD -3.94%
Deferred Tax Assets, Valuation Allowance 23.8M USD +108%
Deferred Tax Assets, Gross 28.4M USD +136%
Operating Lease, Liability 62.1K USD
Depreciation 297 USD -82.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.9M USD -2788%
Lessee, Operating Lease, Liability, to be Paid 59.4K USD +207%
Property, Plant and Equipment, Gross 25.1K USD -1.82%
Operating Lease, Liability, Current 21.2K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 25K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 23.9K USD +18.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.78K USD -65.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 21.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 25.5M USD +181%
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 138M USD +124%
Deferred Tax Assets, Net of Valuation Allowance 23.8M USD +108%
Interest Expense 690K USD +29.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%